RESULTS FROM A PHASE 2 STUDY OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
a Division of Hematology, University of Toronto, Toronto, Canada
b Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
c UCSF Benioff Children's Hospitals, Oakland, United States
d Massachusetts General Hospital, Harvard Medical School, Boston, United States
e Agios Pharmaceuticals, Inc., Cambridge, United States
Lido
2606
Vezesque se leu este artigo
974
Total PDF
1632
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 26 | 11 | 37 |
| 2025 5 | 48 | 12 | 60 |
| 2025 4 | 35 | 16 | 51 |
| 2025 3 | 54 | 15 | 69 |
| 2025 2 | 36 | 9 | 45 |
| 2025 1 | 32 | 23 | 55 |
| 2024 12 | 33 | 17 | 50 |
| 2024 11 | 34 | 20 | 54 |
| 2024 10 | 35 | 29 | 64 |
| 2024 9 | 50 | 17 | 67 |
| 2024 8 | 40 | 20 | 60 |
| 2024 7 | 34 | 23 | 57 |
| 2024 6 | 44 | 30 | 74 |
| 2024 5 | 74 | 33 | 107 |
| 2024 4 | 38 | 11 | 49 |
| 2024 3 | 38 | 23 | 61 |
| 2024 2 | 31 | 19 | 50 |
| 2024 1 | 32 | 19 | 51 |
| 2023 12 | 32 | 18 | 50 |
| 2023 11 | 50 | 29 | 79 |
| 2023 10 | 35 | 33 | 68 |
| 2023 9 | 52 | 41 | 93 |
| 2023 8 | 43 | 26 | 69 |
| 2023 7 | 38 | 15 | 53 |
| 2023 6 | 40 | 12 | 52 |
| 2023 5 | 34 | 22 | 56 |
| 2023 4 | 33 | 15 | 48 |
| 2023 3 | 46 | 26 | 72 |
| 2023 2 | 29 | 11 | 40 |
| 2023 1 | 44 | 18 | 62 |
| 2022 12 | 50 | 16 | 66 |
| 2022 11 | 51 | 26 | 77 |
| 2022 10 | 38 | 21 | 59 |
| 2022 9 | 59 | 46 | 105 |
| 2022 8 | 41 | 25 | 66 |
| 2022 7 | 29 | 26 | 55 |
| 2022 6 | 30 | 28 | 58 |
| 2022 5 | 27 | 23 | 50 |
| 2022 4 | 19 | 22 | 41 |
| 2022 3 | 26 | 23 | 49 |
| 2022 2 | 14 | 19 | 33 |
| 2021 1 | 18 | 23 | 41 |
| 2021 12 | 16 | 28 | 44 |
| 2021 11 | 17 | 29 | 46 |
| 2021 10 | 7 | 6 | 13 |
Mostrar tudo
